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SCD is a major public health problem both at the US and
worldwide. It is estimated that each year in the US 400,000–
460,000 persons die of unexpected SCD in Emergency
Departments or before reaching a hospital. The current man-
agement of SCD is directed at a relatively small percentage
of the total population at risk and primarily at those patients
already known to be at increased risk by conventional criteria.
Pharmaceutical strategies to prevent SCD have been largely
ineffective. Because device therapy [implantable cardioverter-
deﬁbrillator (ICD)] is designed to rescue patients once an event
has already occurred, primary SCD prevention has become
one of today’s most critical public health challenges. Current
conventional risk stratiﬁers for SCD have shown low positive
predictive power either alone or in different combinations.
As of 2005, the main criterion for primary ICD prophylaxis
for SCD has been the presence of organic heart disease
and depressed left ventricular ejection fraction (LVEF).
Unfortunately, depressed LVEF may be a good marker for
total cardiac mortality but is not speciﬁc for SCD resulting
in a signiﬁcant redundancy of this strategy. The cost to the
health care system of sustaining this approach would be
substantial. For the immediate future, attempts to optimize
the selection process for primary ICD prophylaxis that goes
beyond depressed LVEF must continue.
The present article will review the most recent pathophys-
iology and risk stratiﬁcation of SCD in ischemic heart disease,
and its management beyond the current single criterion of
depressed LVEF.2. Coronary artery disease (CAD) and sudden cardiac death
(SCD) cascade (Fig. 1)
The majority of SCD occurs in patients with atherosclerotic
CAD (65–85%) [1]. However, there is considerable evidence
that traditional markers of CAD, such as hypertension,
obesity, smoking, diabetes, and lipid abnormalities, are not
speciﬁc enough to identify patients at high risk for SCD [2].
Patients with similar risk factors for CAD may suffer from
SCD or nonfatal ischemic events. The reason for this differ-
ence is not clear. However, there is exciting evidence in recent
years in genetic studies of CAD and MI that may in part
explain this discrepancy. For example, one disease-causing
gene for CAD and MI has been identiﬁed as MEF2A, which
is located on chromosome 15q26.3 and encodes for a transcrip-
tional factor with a high level of expression in coronary
endothelium [3]. Approximately 1–2% of CAD patients may
carry an MEF2A mutation. Several other susceptibility genes
have been identiﬁed using genome-wide association studies
or genome-wide linkage studies [3].
On the other hand, there is a new understanding of the cas-
cade that relates the distal events of atherosclerosis to the
proximal event of SCD. New risk markers for SCD in CAD
are likely to cluster under factors that may directly facilitate
the development of acute coronary syndromes, speciﬁcally
those factors that may facilitate transient triggering events,
including plaque rupture, enhanced thrombogenesis, and
coronary artery spasm [4,5]. There are signiﬁcant data showing
correlation between SCD and
(1) markers of plaque vulnerability, such as heritable alter-
ations of speciﬁc matrix metalloproteinases [6];
(2) markers of enhanced thrombogenesis, such as increased
D-dimer, increased apo-B, and decreased apo-A1 [7]; as
well as polymorphism in platelet glycoprotein receptors
[8];
(3) genetic variations that predispose to vasospasm, such as
variations in the vascular endothelial nitric oxide syn-
thetase (eNOS) system [9,10]; and
(4) markers of inﬂammatory response, such as C-reactive
protein (CRP) [11].
Figure 1 Abbreviations: CAD, coronary artery disease; EP,
electrophysiological; ICD, implantable cardioverter deﬁbrillator;
MI, myocardial infarction; SCD, sudden cardiac death; VT/VF,
ventricular tachycardia/ventricular ﬁbrillation.
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physiological vulnerability leading to fatal ventricular
tachyarrhythmia and SCD (unless the patient has a prior
ICD) or in nonfatal myocardial infarction (MI). In patients
who survive a nonfatal MI the heart undergoes a complex
post-MI remodeling process that in the long run results in
increased electrophysiological vulnerability, fatal ventricular
tachyarrhythmia, and SCD or in progressive deterioration of
ventricular systolic function, ischemic cardiomyopathy,
congestive heart failure, and non-SCD.
3. Diabetes, CAD, and Risk of SCD
Cardiovascular disease is the leading cause of death in
individuals with type 2 diabetes, which affects about 15 million
Americans [12]. This is compatible with the ‘‘common soil’’
hypothesis, which postulates that both diabetes and cardio-
vascular disease have common genetic and environmental
antecedents, i.e., ‘‘they spring from the same soil’’ [13]. There
is evidence that diabetes is a signiﬁcant risk factor for SCD
but not for nonfatal MI [14]. The increased risk of death and
mortality rates associated with diabetes is compounded by
the fact that many diabetic individuals are unaware that they
suffer from the metabolic syndrome. There is strong evidence
that the elevated risk for cardiovascular disease starts to
increase long before the onset of clinical diabetes, conﬁrming
the so-called ‘‘ticking clock’’ hypothesis [15]. The incidence
of impaired glucose tolerance and diabetes may be as high as
39% and 31%, respectively, in patients admitted with acute
MI [16]. Recent studies have documented increased inﬂamma-
tion, neovascularization, and intraplaque hemorrhage in
human diabetic atherosclerosis [17]. Because of vulnerability
of diabetic patients to plaque rupture and acute MI, a question
of considerable importance is whether patients with CAD,
diabetes or prediabetes, and relatively preserved LV systolic
function (LVEFP 35%) can beneﬁt from primary ICD
prophylaxis.4. The autonomic system and enhanced susceptibility to SCD
Autonomic neural inﬂuences, especially increased adrenergic
and decreased cholinergic activity, can modulate the sus-
ceptibility to SCD following MI. Resting heart rate has been
shown to be an independent risk factor for SCD in middle-
aged men [18]. There are data showing the heritability of heart
rate variation [19]. Adrenergic agonists are known to trigger
ventricular arrhythmias, and their circulating levels have simi-
lar diurnal patterns as SCD events [20]. Genetic polymorphism
of b-adrenergic receptors has been associated with increased
susceptibility to SCD in ischemic heart disease [21]. The
association between plasma nonesteriﬁed fatty acids and
SCD may be related to increased adrenergic tone or the effect
on ion channel and transporters [22]. Further, mental stress
was found to be associated with lateralization of mid brain
activity resulting in imbalanced activity in right and left car-
diac sympathetic nerves and increased dispersion of repolariza-
tion, predisposing to arrhythmia [23]. Recently a third type of
b-adrenergic receptors, b-3 adrenergic receptors were found in
the human heart [24]. In both failing and post-MI myocar-
dium, b-3 adrenergic receptors stimulation may have protec-
tive effects against b-1 and b-2 catecholaminergic stimulation
[25]. This makes b-3 adrenergic receptors a very attractive tar-
get for pharmacologic therapy of cardiac arrhythmias related
to cardiac sympathetic nerve stimulation.5. Cardiac gene mutations and enhanced susceptibility to SCD
There is compelling evidence that a genetic mechanism may
increase patient susceptibility to SCD following MI. Subtle
genetic variations such as single nucleotide polymorphisms
can inﬂuence the phenotypic expression of low penetrance
ion channel mutations and increased the propensity to VA
and SCD [26]. One clue of the role that genetic factors may
play in SCD has been evidence of ‘‘family clustering’’ of
SCD victims. Population studies have reported that familial
clustering of SCD events is an important independent factor
in multifactorial analyses of SCD risk. This may be related
to shared environmental or genetically transmittable abnor-
malities. Evidence favoring a focus on genetic factors was
presented in epidemiologic studies that suggested not only that
familial risks for SCD appear substantial, but that they are
statistically distinct and separable from familial risks of MI
[27–30]. In one study parental history of SCD increased the
relative risk of SCD to 1.8 after adjustment for conventional
CAD risk factors, but it did not elevate the risk for deaths
coded as non-sudden. In a small subset in which there was a
history of both maternal and paternal SCD events, the relative
risk for SCD in offspring was up to 9.4 280.
Further, the role of modiﬁer genes (gene-gene interaction) is
beginning to be appreciated. Modiﬁer genes are genes that are
not involved in the genesis of the disease but modify the sever-
ity of the phenotypic expression. The ﬁnal phenotype is the
result of interactions among causal genes, modiﬁer genes,
and environmental factors. Identiﬁcation of modiﬁer genes will
complement the results of studies of causative genes and could
enhance genetic-based diagnosis, risk stratiﬁcation, and imple-
mentation of preventive and therapeutic measures of SCD [31].
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Patients who suffer from a nonfatal MI as well as those who
survive SCD in the setting of acute MI later undergo post-
MI remodeling. Ventricular remodeling is the process by which
ventricular size, shape and function are regulated by mechani-
cal, neurohormonal, and genetic factors [32–34]. Remodeling
may be physiological and adaptive during normal growth or
pathological due to MI, cardiomyopathy, hypertension, or
valvular heart disease. Post-MI remodeling is a complex
time-dependent process that involves structural, biochemical,
neurohormonal and electrophysiologic alterations. The acute
loss of myocardium results in an abrupt increase in loading
conditions that induces a unique pattern of remodeling involv-
ing the infarcted border zone and remote noninfarcted myo-
cardium [35]. Post-MI remodeling is associated with time-
dependent dilatation, distortion of ventricular shape, and
hypertrophy of the noninfarcted myocardium. Following a
variable period of compensatory hypertrophy, deterioration
of contractile function may develop resulting in congestive
heart failure.
In recent years the understanding of the signal transduction
pathways for cardiac remodeling in the post-MI heart [36,37]
has provided opportunities for novel therapeutic interventions.
Fig. 2 illustrates a proposed scheme for post-MI signaling
pathways 310. Many of these pathways were shown to be acti-
vated either in response to ischemia/reperfusion stimuli or to a
stretch stimulus using different experimental models and some-
times non-cardiac cell systems. However, cell membrane recep-
tors and intracellular signaling proteins are highly conserved
between mammalian species and the triggering events for cellu-
lar hypertrophy in humans are likely to resemble closely those
in the various animal models used. The diagram shows that a
cascade of successive transduction steps allows signal enhance-
ment and diversiﬁcation at branching points and thus permits
combinatorial interactions between multiple pathways.
Although multiple signaling pathways may act in a synergistic,
antagonistic, or permissive way some key pathways may play aFigure 2 Post-MI signaling pathways. Modiﬁed from Hefti MA,
Harder BA, Eppenberger HM, Schaub MC: Signaling pathways in
cardiac myocyte hypertrophy. J Mol Cell Cardiol 1007;29:2873–
2892, with permission of Elsevier.dominant role. There is a plethora of experimental and clinical
evidence showing that the renin-angiotensin system (RAS) and
the b-adrenergic system play major roles in post-MI remodel-
ing [34]. This explains the beneﬁcial role that ACE inhibitors,
AT-1 receptor antagonists, and beta-blockers in the post-MI
period. More recently, other signaling pathways, for example,
the calcineurin pathway 380 and the Janus kinase/signal trans-
ducer and activator of transcription (JAK-STAT) [39] signal-
ing pathway were also found to play a signiﬁcant role in
post-MI remodeling. Pharmaceutical agents that can block
these pathways may provide new therapeutic modalities in
the post-MI period.
7. Post-MI remodeling and electrophysiological vulnerability
A key electrophysiological alteration in post-MI remodeled
heart is down regulation of K+ gene expression and K+ cur-
rents resulting in spatially heterogeneous prolongation of
action potential duration and increased dispersion of refrac-
toriness [40]. For many years the observation was made that
cardiac hypertrophy from whatever cause is consistently
associated with down regulation of K+ channel genes and
K+ currents. However, recent studies have shown that, in
the post-MI heart, this down regulation occurs early and
may be dissociated from the slower time course of post-MI
remodeled hypertrophy [40]. It is therefore not surprising that
the post-MI heart is more sensitive to hypokalemia and the
proarrhythmic effects of drugs that depress K+ currents, espe-
cially Ikr blockers. Some pharmacological interventions that
have been shown to reduce the incidence of SCD in post-MI
patients, like magnesium [41] and spironolactone [42] may
act by countering the effects of low K+.8. SCD and systolic dysfunction
Although the exact mechanisms involved in the strong cor-
relation between decreased left ventricular (LV) systolic func-
tion and increased incidence of SCD are not clearly deﬁned,
it is now recognized that one way to combat SCD following
MI is to try to halt or improve the deterioration in LV func-
tion. The mechanism(s) for the transition from compensated
to decompensated heart failure is under intensive investigation
and it is clear that multiple factors are involved [43]. The role
of continuous loss of cardiomyocytes to apoptosis in the non-
infarcted myocardium; the negative consequences of remodel-
ing of the interstitial matrix; the downregulation of the beta-
adrenergic receptor-G protein-adenylyl cyclase pathway; the
downregulation of the L-type calcium current, and the alter-
ations in calcium regulated excitation–contraction coupling
are some of the major mechanisms involved. Recent years have
seen signiﬁcant advances in the treatment of ventricular sys-
tolic dysfunction and heart failure. The therapeutic armamen-
tarium includes not only pharmacological agents, but also
electrical and surgical devices. Besides the cornerstone drugs
for heart failure like digoxin, diuretics, ACE inhibitors, and
beta-blockers, newer agents like the aldosterone receptor
antagonist spironolactone, the endothelin antagonist bosen-
tan, the vasopeptidase inhibitor omapatrilat, and the brain
natriuretic peptide (BNP) nesiritide have been investigated in
multicenter trials with varying results 440. BNP level was
shown to be a strong predictor of SCD in patients with chronic
Table 1 Risk stratiﬁcation of SCD.
Electrophysiological surrogates Functional, biochemical, and genetic surrogates
Measures of conduction disorder: SAECG, % of scar tissue in CMR Functional markers:
– LVEFa
Measures of dispersion of repolarization: QT dispersion, TWA – NYHA Class
Measures of autonomic nervous system:
(a) Direct: sympathetic nerve activity, 1231-MIBG scan




– Serum matrix metalloproteinase
– BNP, etc
Measures of altered calcium kinetics ??? Genetic Markers ???
Abbreviations: BNP, beta natriuretic peptide; CMR, cardiac magnetic resonance; HR, heart rate; HRV, heart rate variability; LVEF, left
ventricular ejection fraction; NYHA, New York Heart Association; SAECG, signal averaged electrocardiogram; SCD, sudden cardiac death;
TWA, microvolt T-wave alternans.
a Currently, LVEF 6 35% is the main criterion for primary ICD prophylaxis.
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biventricular pacing in selected groups of patients can improve
LVEF and mortality [46]. Further, surgical procedures like
passive external support have been shown in experimental
studies to reverse remodeling with reduced systolic wall stress
and improved adrenergic signaling [47]. The success of the
LV assist devices [48] has shown that even in an advanced
stage of heart failure, the remodeling process could be reversed
with a signiﬁcant improvement of ventricular function.
Finally, clinical research has demonstrated that gene transfer
is a potential therapeutic option to restore diseased cardiomy-
ocytes and rescue the failing heart [49].
9. Risk stratiﬁcation of SCD in the post-MI period (Table 1)
In 2005, the Centers for Medicare and Medicaid Services
(CMS) approved primary implantable cardiac cardioverter
deﬁbrillator (ICD) for patients in the post-MI period who have
LVEF of 35% and New York Heart Association (NYHA)
class II or III heart failure [50]. These criteria were based on
data from MADIT II [51] and SCD-HeFT [52]. Implantation
is approved only after 40 days or more have elapsed from
the time of MI, on the basis of data from DINAMIT [53].
One area of uncertainty of these criteria is the unreliability
of LVEF measurements as well as evolution of LVEF over
time and the way in which this inﬂuences risk [54]. There is
general consensus that there is a need for more robust risk
stratiﬁcation of SCD beyond LVEF.
All completed SCD primary ICD prophylaxis trials
addressed patients with one or more conventional risk factors
for SCD (Table 1) [31]. The electrophysiological surrogates for
SCD, including measures of myocardial conduction disorders,
dispersion of repolarization, and autonomic imbalance, are
based on sound scientiﬁc evidence. However, the majority of
conventional electrophysiological risk stratiﬁers of SCD have
a relatively low positive predictive value that would preclude
their wide application as guidelines for ICD implantation in
patients known to be at risk for SCD. This is not to mention
the impracticality of their use for risk stratiﬁcation in the gen-
eral asymptomatic public. It is not therefore surprising that the
current main criteria for SCD primary ICD prophylaxis are
measures of ventricular dysfunction, i.e., LVEF and NYHA
class. There is general consensus that these criteria may havestrong predictive value for total cardiac mortality but are not
speciﬁc enough for arrhythmic mortality. This explains the
continued effort to identify additional risk factors with
independent or additive predictive power for arrhythmic
death. These may include the use of newer techniques of
nuclear magnetic resonance with contrast material to deﬁne
anatomy of the infarct [55] as well as possible future use of
genetic risk proﬁling.
10. Conclusions
The immediate future goals for risk stratiﬁcation and manage-
ment of SCD post-MI could be summarized as follows: (1)
identiﬁcation of novel clinical, biochemical, and genetic mark-
ers for SCD and assessment of the functional consequences of
sequence variants identiﬁed in human genetic studies as well as
relevant environmental-genetic interactions. (2) Determination
of the heritability of genetic risk factors for SCD as well as the
factors involved in ethnic-speciﬁc differences in risk of SCD.
(3) Identiﬁcation of a battery of a relatively limited number
of incrementally cumulative low-intermediate risk variants
and development of a ‘‘signature’’ combination of clinical, bio-
chemical, and genetic markers of SCD. However, we should
not be surprised that the positive predictive value of some of
the new risk factors, similar to conventional risk factors, will
be relatively low, especially if these are applied to large pop-
ulations who are at low risk. In fact, the true value of risk
stratiﬁcation of SCD in the future may be to identify low-risk
populations who do not warrant prophylactic intervention
with therapy that demonstrated efﬁcacy, e.g. the ICD. (4)
Identiﬁcation of novel pharmacological and non-pharmaco-
logical approaches for risk modiﬁcation and prevention of
SCD. One example is the interest in clinical prevention of
SCD by n-3 polyunsaturated fatty acids. Although this rela-
tively new diet-heart hypothesis that underlies this therapeutic
modality is yet to catch the attention of the clinical community
at large, several experimental and clinical evidence points to
the validity of this approach [56]. (5) Wider collaboration
among different academic and industrial institutions by shar-
ing research results as well as resources such as clinical data,
blood and other tissues from Biorepository centers. The ulti-
mate goal is not only to change the current direction of man-
agement strategy of SCD away from increased ICD utilization,
Editorial 21but primarily to identify novel methods for risk stratiﬁcation,
risk modiﬁcation, and prevention of SCD that could be
applied to the general public at large.
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